Piramal Snags Imaging Agents From Bayer | Chemical & Engineering News
Volume 90 Issue 17 | p. 19 | Concentrates
Issue Date: April 23, 2012

Piramal Snags Imaging Agents From Bayer

Department: Business
Keywords: Alzheimer’s disease, molecular imaging

Piramal Healthcare will acquire Bayer’s molecular-imaging R&D portfolio for an undisclosed sum. The portfolio includes rights to florbetaben, a diagnostic that detects amyloid-β plaque deposits in the brain. The plaque is considered an indicator of Alzheimer’s disease. Piramal says the portfolio has a potential value of $1.5 billion. The deal marks Piramal’s second acquisition of a late-stage asset; last year, the Indian firm bought a cartilage repair product that has since been approved in Europe.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment